
Autolus Therapeutics (AUTL) Stock Forecast & Price Target
Autolus Therapeutics (AUTL) Analyst Ratings
Bulls say
Autolus Therapeutics PLC is anticipated to experience substantial revenue growth, with projections for fiscal year 2026 estimating sales to reach $167 million, reflecting a significant year-over-year increase of approximately 220%, which surpasses existing consensus estimates. This expected sales acceleration is bolstered by improved margins resulting from increased operational scale, likely leading to enhanced profitability. Additionally, the company's Aucazyl product has demonstrated statistically significant safety improvements, positioning it as a potentially preferred treatment in the landscape of CAR-T therapies for relapsed/refractory acute lymphoblastic leukemia (r/r ALL).
Bears say
The analysis of Autolus Therapeutics indicates a negative outlook due to disappointing early-stage clinical results, specifically concerning the production forecasts for CAR-T therapeutics, which may not meet expectations based on the limited patient cohort data. Investors remain skeptical about the company's ability to achieve break-even, particularly in light of adverse outcomes such as one patient experiencing morphological relapse and another showing emerging minimal residual disease (MRD). Additionally, the sum-of-the-parts (SOTP) analysis reflects cautious sentiment, applying a reduced discount rate to the estimated sales potential, suggesting a diminished confidence in the pipeline's growth trajectory.
This aggregate rating is based on analysts' research of Autolus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Autolus Therapeutics (AUTL) Analyst Forecast & Price Prediction
Start investing in Autolus Therapeutics (AUTL)
Order type
Buy in
Order amount
Est. shares
0 shares